David Fenard

1.4k total citations
36 papers, 1.1k citations indexed

About

David Fenard is a scholar working on Molecular Biology, Genetics and Virology. According to data from OpenAlex, David Fenard has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Genetics and 12 papers in Virology. Recurrent topics in David Fenard's work include Virus-based gene therapy research (17 papers), HIV Research and Treatment (12 papers) and RNA Interference and Gene Delivery (11 papers). David Fenard is often cited by papers focused on Virus-based gene therapy research (17 papers), HIV Research and Treatment (12 papers) and RNA Interference and Gene Delivery (11 papers). David Fenard collaborates with scholars based in France, United States and Slovakia. David Fenard's co-authors include Warner C. Greene, Samuel A. Williams, Alain Doglio, Gérard Lambeau, Marielle Cavrois, Hakju Kwon, Dwayne A. Bisgrove, Jean‐Claude Lefebvre, Lin‐Feng Chen and Eric Verdin and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David Fenard

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Fenard France 18 552 457 364 294 285 36 1.1k
Maxime Moulard France 16 842 1.5× 378 0.8× 565 1.6× 380 1.3× 74 0.3× 37 1.3k
Prakash Sista United States 18 807 1.5× 507 1.1× 359 1.0× 795 2.7× 218 0.8× 29 1.6k
Youn Tae Kwak United States 11 368 0.7× 709 1.6× 269 0.7× 226 0.8× 70 0.2× 11 1.1k
Rachel Van Duyne United States 23 526 1.0× 829 1.8× 447 1.2× 432 1.5× 74 0.3× 43 1.5k
Miguel Muñoz Switzerland 20 586 1.1× 568 1.2× 330 0.9× 395 1.3× 131 0.5× 28 1.2k
Jean-Marc Jacqué United States 11 571 1.0× 884 1.9× 431 1.2× 216 0.7× 224 0.8× 11 1.4k
Jane Rasaiyaah United Kingdom 18 717 1.3× 973 2.1× 427 1.2× 399 1.4× 237 0.8× 21 1.7k
Brett D. Welch United States 15 386 0.7× 667 1.5× 140 0.4× 379 1.3× 120 0.4× 18 1.3k
Vladimir A. Morozov Germany 14 358 0.6× 305 0.7× 226 0.6× 264 0.9× 304 1.1× 23 1.1k
Henning Lauterbach Switzerland 15 110 0.2× 494 1.1× 868 2.4× 168 0.6× 170 0.6× 34 1.5k

Countries citing papers authored by David Fenard

Since Specialization
Citations

This map shows the geographic impact of David Fenard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Fenard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Fenard more than expected).

Fields of papers citing papers by David Fenard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Fenard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Fenard. The network helps show where David Fenard may publish in the future.

Co-authorship network of co-authors of David Fenard

This figure shows the co-authorship network connecting the top 25 collaborators of David Fenard. A scholar is included among the top collaborators of David Fenard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Fenard. David Fenard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
David, Marion, Davide Monteferrario, Satish K. Tadi, et al.. (2025). Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. PubMed. 33(2). 200989–200989. 1 indexed citations
2.
David, Marion, Yue Cui, Emma Proïcs, et al.. (2024). MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis. Journal of Neuroinflammation. 21(1). 268–268. 15 indexed citations
3.
Cui, Yue, Sonia Boulakirba, Marion David, et al.. (2024). OP02 IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s Disease. Journal of Crohn s and Colitis. 18(Supplement_1). i3–i3. 2 indexed citations
4.
David, Marion, et al.. (2023). Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible medium. Molecular Therapy — Methods & Clinical Development. 31. 101111–101111. 3 indexed citations
5.
Proïcs, Emma, Marion David, Majid Mojibian, et al.. (2022). Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation. Gene Therapy. 30(3-4). 309–322. 36 indexed citations
6.
Rocha, Sylvie Da, Jérémy Bigot, Fanny Onodi, et al.. (2019). Temporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer. Molecular Therapy — Methods & Clinical Development. 14. 285–299. 9 indexed citations
7.
Vermeer, Louic S., Arnaud Marquette, Jésus Raya, et al.. (2018). Cell-Penetrating Peptides with Antimicrobial, Transfection and Transduction Activities. Biophysical Journal. 114(3). 267a–267a. 1 indexed citations
8.
Majdoul, Saliha, Jérémie Cosette, Éric Bernard, et al.. (2017). Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance the entry of lentiviral vectors into human cells. Journal of Biological Chemistry. 292(45). 18672–18681. 11 indexed citations
9.
Vermeer, Louic S., Loïc Hamon, Jérémie Cosette, et al.. (2017). Vectofusin-1, a potent peptidic enhancer of viral gene transfer forms pH-dependent α-helical nanofibrils, concentrating viral particles. Acta Biomaterialia. 64. 259–268. 31 indexed citations
10.
Piovan, Claudia, Virna Marin, Cinzia Scavullo, et al.. (2017). Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes. Molecular Therapy — Methods & Clinical Development. 5. 22–30. 16 indexed citations
11.
Fenard, David, et al.. (2016). Production of Retrovirus-Based Vectors in Mildly Acidic pH Conditions. Methods in molecular biology. 1448. 41–48. 3 indexed citations
12.
Majdoul, Saliha, et al.. (2015). Molecular Determinants of Vectofusin-1 and Its Derivatives for the Enhancement of Lentivirally Mediated Gene Transfer into Hematopoietic Stem/Progenitor Cells. Journal of Biological Chemistry. 291(5). 2161–2169. 30 indexed citations
13.
Majdoul, Saliha, et al.. (2014). Influence of Mildly Acidic pH Conditions on the Production of Lentiviral and Retroviral Vectors. PubMed. 25(3). 178–185. 17 indexed citations
14.
15.
Fenard, David, Laurent Houzet, Éric Bernard, et al.. (2009). Uracil DNA Glycosylase 2 negatively regulates HIV-1 LTR transcription. Nucleic Acids Research. 37(18). 6008–6018. 23 indexed citations
16.
Cavrois, Marielle, Jason Neidleman, Wes Yonemoto, David Fenard, & Warner C. Greene. (2004). HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology. 328(1). 36–44. 55 indexed citations
17.
Williams, Samuel A., Lin‐Feng Chen, Hakju Kwon, et al.. (2004). Prostratin Antagonizes HIV Latency by Activating NF-κB. Journal of Biological Chemistry. 279(40). 42008–42017. 259 indexed citations
18.
Fenard, David, Gérard Lambeau, Thomas Maurin, Jean‐Claude Lefebvre, & Alain Doglio. (2001). A Peptide Derived from Bee Venom-Secreted Phospholipase A2Inhibits Replication of T-Cell Tropic HIV-1 Strains via Interaction with the CXCR4 Chemokine Receptor. Molecular Pharmacology. 60(2). 341–347. 66 indexed citations
19.
Fenard, David, Gérard Lambeau, Emmanuel Di Valentin, et al.. (1999). Secreted phospholipases A2, a new class of HIV inhibitors that block virus entry into host cells. Journal of Clinical Investigation. 104(5). 611–618. 131 indexed citations
20.
Fenard, David, et al.. (1998). 3′-End Modification of the Adenoviral VA1 Gene Affects Its Expression in Human Cells: Consequences for the Design of Chimeric VA1 RNA Ribozymes. Antisense and Nucleic Acid Drug Development. 8(5). 379–390. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maxime Moulard Breakdown of academic impact, for papers by Prakash Sista Breakdown of academic impact, for papers by Youn Tae Kwak Breakdown of academic impact, for papers by Rachel Van Duyne Breakdown of academic impact, for papers by Miguel Muñoz Breakdown of academic impact, for papers by Jean-Marc Jacqué Breakdown of academic impact, for papers by Jane Rasaiyaah Breakdown of academic impact, for papers by Brett D. Welch Breakdown of academic impact, for papers by Vladimir A. Morozov Breakdown of academic impact, for papers by Henning Lauterbach
Rankless by CCL
2026